Recent literature strengthens the evidence of a pathological link between hepatic metabolic alterations (NAFLD or MAFLD) and peripheral artery disease.
Is there a pathological link between metabolic dysfunction-associated steatotic liver disease (MASLD/NAFLD) and peripheral artery disease (PAD)?
This review highlights the emerging evidence linking metabolic dysfunction-associated steatotic liver disease (MASLD) to an increased risk of peripheral artery disease (PAD).
Background: Peripheral artery disease (PAD) is still the least studied and evaluated form in clinical practice among atherosclerotic pathologies, despite the increased mortality and comorbidities related to it. The relationship between steatotic liver disease and an increased risk of cardiovascular disease has been extensively documented. Methods: The purpose of this work is to perform a review of the evidence linking NAFLD or MASLD to PAD, and examine possible clinical scenarios that arise from this new terminology. Results: The new definition of metabolic dysfunction-associated steatotic liver disease (MASLD) includes the presence of cardiometabolic risk factors and hepatic steatosis without any other underlying causes of hepatic steatosis; this terminology, coined in the hepatological field, could generate confusion, especially in the initial stages of its diffusion and among different medical specialists. Conclusions: Some recent data in the literature have strengthened the evidence of a pathological link between hepatic metabolic alteration (NAFLD or MAFLD) and PAD.
Boccatonda et al. (Thu,) conducted a review in Peripheral artery disease (PAD) and metabolic dysfunction-associated steatotic liver disease (MASLD). Recent literature strengthens the evidence of a pathological link between hepatic metabolic alterations (NAFLD or MAFLD) and peripheral artery disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: